Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil, Switzerland, near Basel, focused on discovering and developing innovative drugs for rare diseases and central nervous system disorders. The company was founded in 2017 as a spin-off from Actelion, following Johnson & Johnson's acquisition of Actelion.
Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil, Switzerland, near Basel, focused on discovering and developing innovative drugs for rare diseases and central nervous system disorders. The company was founded in 2017 as a spin-off from Actelion, following Johnson & Johnson's acquisition of Actelion.
Overview
Mermaid diagram (expand to render)
Idorsia was established with a portfolio of promising clinical and preclinical compounds from Actelion's pipeline, along with a team of experienced drug hunters. The company operates with a dual focus on rare diseases and CNS disorders, leveraging its expertise in GPCR pharmacology and drug discovery["@idorsiaa"].
Funding
IPO: 2017 (SIX: IDIA)
Market Cap: ~$1B
Corporate Structure
Headquarters: Allschwil, Switzerland
Research Site: Belp, Switzerland
US Operations: San Diego, California
Employees: Approximately 500
History
Spin-off from Actelion (2017)
Idorsia was created in 2017 when Johnson & Johnson acquired Actelion for $30 billion. As part of the deal, Actelion's pipeline assets and research team were spun out to form Idorsia, with Jean-Paul and Martine Clozel (former Actelion leadership) leading the new company.
IPO and Growth (2017-2024)
June 2017: IPO on SIX Swiss Exchange, raising approximately CHF 275 million
2018-2022: Advanced clinical programs in insomnia, Fabry disease, and subarachnoid hemorrhage
2022: FDA approval of QUVIVIQ (daridorexant) for insomnia
ACT-777991: Immunomodulatory agent for rare diseases
ACT-541232: Novel GPCR-targeted compound
ACT-777106: Rare disease candidate
Key Pipeline Highlights
Daridorexant (QUVIVIQ)
Daridorexant represents a novel mechanism for insomnia treatment. Unlike traditional hypnotics that target GABA receptors, daridorexant blocks orexin neuropeptides that promote wakefulness[@daridorexanta]:
Mechanism: Dual orexin receptor antagonist (DORA)
Dosing: Once-nightly oral tablet
Clinical Benefits: Improved sleep onset and maintenance without next-day sedation
Market Position: Competes with Merck's Belsomra (suvorexant)
Clinical Trials: Phase 3 trials showed significant improvement in sleep efficiency and patient-reported outcomes
Lucerastat
Lucerastat is a substrate reduction therapy for Fabry disease:
Mechanism: Inhibits glucosylceramide synthase to reduce GL-3 accumulation
Oral Administration: Potential alternative to enzyme replacement therapy
Phase 3 Results: Primary endpoint not met but showed biochemical efficacy in reducing Gb3 isoforms[@lucerastat]
Clazosentan
Clazosentan is an endothelin-A receptor antagonist being developed to prevent cerebral vasospasm following aneurysmal subarachnoid hemorrhage:
Phase 3: Completed, showing reduction in vasospasm-related complications
Science and Technology
GPCR Expertise
Idorsia's platform is built on deep expertise in G protein-coupled receptor (GPCR) pharmacology. This class of receptors includes many druggable targets for CNS and metabolic disorders:
Orexin receptors (sleep-wake regulation)
[Dopamine](/mechanisms/dopaminergic-signaling) receptors (movement and reward)
Endothelin receptors (vascular function)
Serotonin receptors (mood and cognition)
Drug Discovery Engine
The company maintains a discovery engine capable of:
Structure-based drug design
High-throughput screening
Medicinal chemistry optimization
Clinical development execution
Neurological Relevance
Idorsia's CNS pipeline has significant implications for neurodegenerative and neurological disorders[@idorsiab]:
Sleep Disorders: Daridorexant represents a paradigm shift in insomnia treatment with a novel mechanism that avoids dependence and withdrawal issues associated with benzodiazepines.
Parkinson's Disease: Aplindore targets dopamine D2 receptors with a different pharmacological profile than current dopamine agonists, potentially offering benefits with reduced side effects.
Epilepsy: ACT-709478 represents a novel anticonvulsant mechanism.
Neuroprotection: The company's GPCR expertise positions it to develop neuroprotective agents.
Financial Highlights
Initial Public Offering: June 2017 (SIX Swiss Exchange)
Market Cap: Approximately $2 billion CHF
Key Investor: Johnson & Johnson (former Actelion stake)
Cash Position: Approximately CHF 500 million (as of 2024)
Collaborations
Idorsia has established partnerships to support its development programs:
Janssen Biotech: Collaboration on immunology programs
CeMM (Vienna): Research collaboration on rare diseases
Academic collaborations: Multiple university partnerships for target validation